Penserra Capital Management LLC Buys New Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Penserra Capital Management LLC purchased a new stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 19,600 shares of the specialty pharmaceutical company's stock, valued at approximately $757,000. Penserra Capital Management LLC owned 0.06% of Collegium Pharmaceutical at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the company. Pacer Advisors Inc. raised its stake in shares of Collegium Pharmaceutical by 31.8% in the second quarter. Pacer Advisors Inc. now owns 3,408,369 shares of the specialty pharmaceutical company's stock worth $109,749,000 after purchasing an additional 821,541 shares during the last quarter. Rubric Capital Management LP grew its position in shares of Collegium Pharmaceutical by 27.2% during the second quarter. Rubric Capital Management LP now owns 2,333,500 shares of the specialty pharmaceutical company's stock worth $75,139,000 after purchasing an additional 499,473 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Collegium Pharmaceutical by 0.8% in the first quarter. Vanguard Group Inc. now owns 2,330,728 shares of the specialty pharmaceutical company's stock worth $90,479,000 after buying an additional 17,942 shares in the last quarter. Principal Financial Group Inc. boosted its holdings in shares of Collegium Pharmaceutical by 3.9% during the 3rd quarter. Principal Financial Group Inc. now owns 1,745,818 shares of the specialty pharmaceutical company's stock valued at $67,459,000 after purchasing an additional 64,958 shares during the last quarter. Finally, Renaissance Technologies LLC increased its stake in Collegium Pharmaceutical by 8.0% in the 2nd quarter. Renaissance Technologies LLC now owns 1,531,498 shares of the specialty pharmaceutical company's stock worth $49,314,000 after acquiring an additional 113,300 shares during the last quarter.

Insider Activity

In related news, EVP Shirley R. Kuhlmann sold 19,248 shares of the stock in a transaction on Thursday, September 5th. The stock was sold at an average price of $38.30, for a total value of $737,198.40. Following the completion of the transaction, the executive vice president now directly owns 120,161 shares of the company's stock, valued at approximately $4,602,166.30. This represents a 13.81 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Thomas B. Smith sold 9,593 shares of the stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $36.62, for a total transaction of $351,295.66. Following the completion of the sale, the executive vice president now owns 53,816 shares of the company's stock, valued at $1,970,741.92. This trade represents a 15.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 3.98% of the company's stock.

Collegium Pharmaceutical Price Performance

Shares of Collegium Pharmaceutical stock traded down $0.48 on Thursday, hitting $30.71. The company's stock had a trading volume of 682,214 shares, compared to its average volume of 447,095. The company has a market capitalization of $990.40 million, a price-to-earnings ratio of 13.24 and a beta of 0.95. The firm has a fifty day moving average price of $35.28 and a 200-day moving average price of $34.65. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97. Collegium Pharmaceutical, Inc. has a 1 year low of $25.16 and a 1 year high of $42.29.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on COLL shares. StockNews.com downgraded Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, October 23rd. Needham & Company LLC reissued a "hold" rating on shares of Collegium Pharmaceutical in a research report on Friday, August 9th. HC Wainwright lifted their price objective on Collegium Pharmaceutical from $47.00 to $50.00 and gave the company a "buy" rating in a report on Thursday, September 5th. Piper Sandler restated a "neutral" rating and issued a $37.00 price target on shares of Collegium Pharmaceutical in a report on Friday, October 11th. Finally, Truist Financial lifted their price target on Collegium Pharmaceutical from $40.00 to $42.00 and gave the company a "buy" rating in a report on Friday, August 9th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $42.60.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.